Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

2 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Adalimumab, phototherapy improve QoL in psoriasis patients

20 Sep 2019

Both adalimumab and phototherapy increase overall and skin-related quality of life (QoL) in psoriasis patients, although phototherapy appears to be better, a recent study has shown.

Researchers randomly assigned 97 psoriasis patients to receive phototherapy (n=33; mean age, 42.0±14.0 years; 69.7 percent male), adalimumab (n=33; mean age, 44.2±14.0 years; 72.7 percent male) or placebo (n=31; mean age, 44.3±14.5 years; 60.5 percent male). QoL outcomes were measured every 4 weeks using the Dermatology Life Quality Index (DLQI) and the three-level version of the five-dimension EuroQol (EQ-5D-3L) tool.

At baseline, the mean DLQI scores in the placebo, adalimumab and phototherapy arms were 12.13, 13.67 and 12.79, respectively. Corresponding scores in the EQ-5D index were 0.80, 0.78 and 0.72. After 12 weeks, statistically significant improvements in skin-related health-related QoL were reported in all groups.

However, both the adalimumab (difference, –3.80, 95 percent CI, –7.64 to 0.04) and phototherapy (difference, –4.80, –8.67 to –0.93) interventions produced significantly greater change relative to placebo.

Similarly, both adalimumab- (odds ratio [OR], 2.88, 1.02–8.17) and phototherapy-treated patients (OR, 8.83, 2.47–31.57) were significantly more likely to reach clinically meaningful improvement, as assessed by DLQI, than their placebo-treated counterparts.

Phototherapy was also more likely than adalimumab to elicit changes that achieved the minimal clinically important difference, although falling short of statistical significance (OR, 3.07, 0.85–11.13).

Both active treatments similarly outperformed placebo in terms of generic health-related QoL, inducing significantly greater improvements in EQ-5D-3L scores by week 12.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

2 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.